» Articles » PMID: 18180098

PIK3CA Gene Mutations and Amplifications in Uterine Cancers, Identified by Methods That Avoid Confounding by PIK3CA Pseudogene Sequences

Overview
Journal Cancer Lett
Specialty Oncology
Date 2008 Jan 9
PMID 18180098
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

PIK3CA codes for a Class IA p110-alpha catalytic subunit of the PI3Ks (phosphatidylinositol 3-kinases) that regulate various signaling pathways important for neoplasia, including cell proliferation, motility, adhesion, and survival. Pro-oncogenic mutations in exons 9 and 20 of the PIK3CA gene have been frequently observed in numerous types of human malignancies. Amplification of the PIK3CA gene has been reported in uterine cervical cancers. In this study, we have done in depth analysis of uterine cervical and endometrial cancers for PIK3CA gene mutations and amplifications. In uterine cervical cancers, PIK3CA mutations were found in 3 of 22 cases (14%), all of them in exon 9. In endometrial cancers, a similar incidence of mutations was found, in 3 of 29 cases (10%), however they were all within exon 20. Amplification of the PIK3CA gene was also detected in 2 out of 22 (9%) cervical cancers and 3 out of 29 (10%) endometrial cancers. In this study, we were unable to find a clear association between PIK3CA mutations and gene amplifications, nor with tumor histological subtypes or staging. Mutations and amplifications of the PIK3CA gene are relatively infrequent in human cervical and endometrial cancers; however, PIK3CA gene alteration may still play a role in some subset of uterine cancers.

Citing Articles

Molecular Heterogeneity of Cervical Cancer Among Different Ethnic/Racial Populations.

Chandra S, Goswami A, Mandal P J Racial Ethn Health Disparities. 2021; 9(6):2441-2450.

PMID: 34741276 DOI: 10.1007/s40615-021-01180-8.


Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection.

Thirunavukarasu D, Cheng L, Song P, Chen S, Borad M, Kwong L Genome Biol. 2021; 22(1):227.

PMID: 34482832 PMC: 8419911. DOI: 10.1186/s13059-021-02449-1.


Ellagic acid exerts antitumor effects via the PI3K signaling pathway in endometrial cancer.

Wang Y, Ren F, Li B, Song Z, Chen P, Ouyang L J Cancer. 2019; 10(15):3303-3314.

PMID: 31293633 PMC: 6603400. DOI: 10.7150/jca.29738.


Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer.

Rodriguez-Freixinos V, Ruiz-Pace F, Farinas-Madrid L, Garrido-Castro A, Villacampa G, Nuciforo P ESMO Open. 2019; 4(2):e000444.

PMID: 30962959 PMC: 6435251. DOI: 10.1136/esmoopen-2018-000444.


Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.

Malentacchi F, Turrini I, Sorbi F, Projetto E, Castiglione F, Fambrini M Oncol Rep. 2018; 41(3):1560-1574.

PMID: 30569174 PMC: 6365709. DOI: 10.3892/or.2018.6939.